Mounjaro vs. New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight

Mounjaro vs. New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight

Send a text

Episode Timeline & Main Topics

00:00 — Opening & Community Update
• First week doing the podcast fully live thanks to the On The Pen community
• Overview of why this week’s news is a major turning point in obesity medicine

02:30 — Introducing the “One-and-Done” Obesity Drug (Wave Life Sciences)
• WVE-007 early data drops
• Why this therapy is unlike GLP-1s or any nutrient-stimulated hormone
• Fat loss results and lean-mass increase

06:30 — How Wave-007 Works: INHBE Gene Silencing
• Mechanism behind visceral fat reduction
• Why this shifts the field toward “quality of weight loss”

09:15 — Why Lean-Mass Preservation Matters
• Current GLP-1 medications and muscle loss
• Why women dominate trial enrollment and the larger implications
• Medicare patients and the coming wave of GLP-1 coverage

13:45 — The Future of Maintenance Therapies
• Fractyl Health Revita results
• Lilly’s orforglipron maintenance design
• Why “holding the line” after GLP-1 therapy is the next major category

17:30 — Amylin Agonists: Cagrelintide vs. Eloralintide
• Novo’s delays and the strategy behind them
• Lilly’s surprising phase 2 results (up to 20% weight loss)
• Combination therapies with tirzepatide or retatrutide

22:30 — FDA Pipeline Acceleration
• Potential removal of traditional phase 3 trials
• How this speeds up the arrival of next-generation therapies

24:15 — Oral GLP-1 Small Molecules (Structure Therapeutics)
• Alaniglipron data and the stock surge
• Comparisons to orforglipron and past failures like denuglipron
• Why Dave remains skeptical

28:40 — Sponsor Break: Shed & Shapa
• Access, coaching, and patient support
• Using a numberless scale to build a healthier relationship with weight tracking

31:10 — Counterfeit Ozempic Warning
• New fake lot discovered in U.S. pharmacies
• How to identify counterfeit pens
• Why this should be a national headline
• The broader question of drug supply-chain vulnerability

36:00 — Closing Thoughts on the Future of Obesity Medicine
• Moving from “more weight loss” to “better weight loss”
• Why the field is closer than ever to reshaping obesity as a disease
• Gratitude for the community making full-time coverage possible

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv


📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(207)

  We’re Solving Obesity. Now Who Pays for It?

We’re Solving Obesity. Now Who Pays for It?

This week on On The Pen, the GLP-1 story is moving in two very different directions.The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its con...

2 Sep 24min

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks ...

26 Aug 34min

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America.But gett...

18 Aug 45min

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

Https://www.otplinks.comBased on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are estimated from speaking ...

12 Aug 31min

Eli Lilly Earnings Call Recap: Retatrutide News

Eli Lilly Earnings Call Recap: Retatrutide News

https://www.otplinks.com

7 Aug 59min

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes i...

4 Aug 18min

Retatrutide Biologic Battle: The Story Gets Bigger

Retatrutide Biologic Battle: The Story Gets Bigger

https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks understand.This breakdown cov...

28 Jul 20min

GLP-1 Showdown: Inside The High Stakes War over Patients

GLP-1 Showdown: Inside The High Stakes War over Patients

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode...

22 Jul 27min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
psykodrama
hvordan-har-du-det-mann
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
leger-om-livet
rss-skravla-gar
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
foreldreradet
morten-ramm-lar-kakla-ga-til-du-sovner
g-punktet
klimaks
hjernesterk
rss-lopedrommen
hormonelle-frida
kjed-deg-i-sovn-verdens-kjedeligste-podcast
hverdagspsyken
sinnsyn
treningsprat